Table 1.
Demographic and clinical characteristics of the study cohort.
| Characteristic | No. (%) of patients (n = 33)a |
Mean (SD) | Median |
|---|---|---|---|
| Demographic | |||
| Age, years | 34.09 (6.67) | 34.00 | |
| Race | |||
| White | 5 (15.15) | ||
| Black | 22 (66.67) | ||
| Other | 6 (18.18) | ||
| Antiretroviral therapy | |||
| None | 12 (37.50) | ||
| Monotherapy | 2 (6.25) | ||
| Combination without PI | 6 (18.75) | ||
| Combination with PI | 12 (37.50) | ||
| Clinical covariate | |||
| CD4+ cell count, cells/mm3 | 400.64 (263.23) | 359.00 | |
| <200 | 6 (18.18) | ||
| 200–499 | 18 (54.55) | ||
| ≥500 | 9 (27.27) | ||
| HIV RNA level, copies/mLb | |||
| Blood | 163,822 (638,584) | 15,000 | |
| Detectable | 26 (78.79) | ||
| Undetectable | 7 (21.21) | ||
| CVL | 5976 (12,812) | 80 | |
| Detectable | 17 (51.52) | ||
| Undetectable | 16 (48.48) | ||
| Saliva | 9866 (21,964) | 2200 | |
| Detectable | 7 (58.33) | ||
| Undetectable | 5 (41.67) | ||
| Cytokine level, pg/mL | |||
| TNFR2 | |||
| CVL supernatant | 137.93 (166.13) | 50.00 | |
| Plasma | 6154.38 (4558.71) | 4746.00 | |
| IFN-γ | |||
| CVL supernatant | 2.33 (5.87) | 1.00 | |
| Plasma | 1.00 (0.00) | 1.00 | |
| IL-1β | |||
| CVL supernatant | 51.62 (124.61) | 7.47 | |
| Plasma | 0.98 (1.12) | 0.50 | |
| IL-6 | |||
| CVL supernatant | 17.31 (42.86) | 5.90 | |
| Plasma | 0.84 (0.74) | 0.50 | |
| IL-8 | |||
| CVL supernatant | 913.69 (1718.87) | 179.19 | |
| Plasma | 3.03 (4.68) | 1.00 | |
| IL-10 | |||
| CVL supernatant | 19.93 (83.64) | 1.50 | |
| Plasma | 1.81 (0.83) | 1.50 |
NOTE.
Combination antiretroviral therapy was defined as 2 nucleoside reverse-transcriptase inhibitors. CVL, cervicovaginal lavage; IFN, interferon; IL, interleukin; PI, protease inhibitor; TNFR2, tumor necrosis factor receptor 2.
a
Because of missing data, the no. of patients in each category may not sum to the total sample size.
b
Half the lower limit of detection was used to estimate values for women with undetectable HIV RNA measurements.